Capital Investment Advisory Services’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.4M | Buy |
8,697
+166
| +2% | +$170K | 0.64% | 31 |
|
|
2026
Q1 | $7.85M | Sell |
8,531
-163
| -2% | -$165K | 0.57% | 40 |
|
|
2025
Q4 | $9.34M | Sell |
8,694
-101
| -1% | -$96.6K | 0.66% | 34 |
|
|
2025
Q3 | $6.71M | Buy |
8,795
+40
| +0.5% | +$29.8K | 0.53% | 42 |
|
|
2025
Q2 | $6.83M | Buy |
8,755
+671
| +8% | +$521K | 0.56% | 41 |
|
|
2025
Q1 | $6.68M | Buy |
8,084
+377
| +5% | +$314K | 0.6% | 36 |
|
|
2024
Q4 | $5.95M | Sell |
7,707
-126
| -2% | -$104K | 0.57% | 38 |
|
|
2024
Q3 | $6.94M | Buy |
7,833
+2,585
| +49% | +$2.32M | 0.66% | 34 |
|
|
2024
Q2 | $4.75M | Buy |
5,248
+422
| +9% | +$338K | 0.49% | 43 |
|
|
2024
Q1 | $3.75M | Buy |
4,826
+179
| +4% | +$127K | 0.4% | 55 |
|
|
2023
Q4 | $2.71M | Sell |
4,647
-66
| -1% | -$38.5K | 0.25% | 68 |
|
|
2023
Q3 | $2.53M | Buy |
4,713
+436
| +10% | +$225K | 0.25% | 70 |
|
|
2023
Q2 | $2.01M | Sell |
4,277
-2,105
| -33% | -$883K | 0.2% | 87 |
|
|
2023
Q1 | $2.19M | Sell |
6,382
-1,147
| -15% | -$387K | 0.26% | 79 |
|
|
2022
Q4 | $2.75M | Buy |
7,529
+332
| +5% | +$118K | 0.33% | 63 |
|
|
2022
Q3 | $2.33M | Sell |
7,197
-279
| -4% | -$88.4K | 0.3% | 65 |
|
|
2022
Q2 | $2.42M | Sell |
7,476
-513
| -6% | -$154K | 0.29% | 70 |
|
|
2022
Q1 | $2.29M | Buy |
7,989
+1,039
| +15% | +$267K | 0.25% | 83 |
|
|
2021
Q4 | $1.92M | Buy |
6,950
+1,109
| +19% | +$281K | 0.23% | 95 |
|
|
2021
Q3 | $1.35M | Buy |
5,841
+771
| +15% | +$190K | 0.17% | 120 |
|
|
2021
Q2 | $1.16M | Buy |
5,070
+599
| +13% | +$120K | 0.15% | 135 |
|
|
2021
Q1 | $835K | Sell |
4,471
-89
| -2% | -$17.4K | 0.12% | 170 |
|
|
2020
Q4 | $770K | Buy |
4,560
+304
| +7% | +$45.4K | 0.11% | 183 |
|
|
2020
Q3 | $630K | Sell |
4,256
-374
| -8% | -$57.9K | 0.12% | 167 |
|
|
2020
Q2 | $760K | Sell |
4,630
-80
| -2% | -$12.3K | 0.15% | 130 |
|
|
2020
Q1 | $653K | Buy |
4,710
+1,920
| +69% | +$264K | 0.16% | 126 |
|
|
2019
Q4 | $367K | Sell |
2,790
-41
| -1% | -$4.75K | 0.1% | 203 |
|
|
2019
Q3 | $317K | Hold |
2,831
| – | – | 0.09% | 210 |
|
|
2019
Q2 | $304K | Buy |
2,831
+92
| +3% | +$10.8K | 0.09% | 217 |
|
|
2019
Q1 | $355K | Buy |
2,739
+56
| +2% | +$6.81K | 0.13% | 148 |
|
|
2018
Q4 | $310K | Buy |
2,683
+125
| +5% | +$14K | 0.13% | 145 |
|
|
2018
Q3 | $274K | Buy |
+2,558
| New | +$256K | 0.13% | 174 |
|
Other funds holding LLY
Capital Investment Advisory Services's LLY Position: Q2 2026 in Review
Capital Investment Advisory Services increased its Eli Lilly (LLY) stake by 1.9% in Q2 2026, buying an estimated $170K and bringing the position to 8,697 shares worth $10.4M. The position accounts for 0.64% of the portfolio, ranked #31.
Capital Investment Advisory Services first reported a position in LLY in Q3 2018 and has held it in 32 quarters since. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Capital Investment Advisory Services held 8,697 shares of Eli Lilly worth $10.4M as of Q2 2026.
- Capital Investment Advisory Services bought 166 Eli Lilly shares in Q2 2026, an estimated $170K.
- Eli Lilly made up 0.64% of Capital Investment Advisory Services's portfolio in Q2 2026, its #31 holding.
- Capital Investment Advisory Services first reported a position in Eli Lilly in Q3 2018 and has held it in 32 quarters since.
- 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Capital Investment Advisory Services's 13F filing for Q2 2026, filed 23 Jul 2026.